recognition of pathological disorders can limit the increase in healthcare cost associated with treatment of these diseases. Equally important, biomarkers are needed in therapeutic drug development to appreciate the balance between beneficial and adverse actions of novel drugs at earlier stages of development, thus increasing the efficacy of drug development.